NEW YORK — Two-year results of the HORIZON study showed phacoemulsification combined with a Hydrus microstent significantly lowered IOP compared with phacoemulsification alone, according to a speaker here. In addition, patients who received the Hydrus were statistically more likely to remain medication-free.
“Hydrus-treated eyes had rapid visual recovery with 94% 20/40 or better after 1 week and 98% 20/40 or better after 1 month. The Hydrus study arm had fewer IOP spikes and required less subsequent glaucoma surgery compared to cataract surgery alone,” Thomas W. Samuelson,
Uncategorized